达标治疗策略在类风湿关节炎日常实践中是否真正有效?RA BIODAM队列纵向分析
基于10国571例RA患者、4356次访视的RA BIODAM队列,评估日常实践中遵循达标治疗(T2T)策略是否使更多患者达到缓解。结果显示单次T2T与3个月后DAS44缓解无显著关联,但持续T2T可提高DAS44缓解可能性,对更严格缓解定义(CDAI、SDAI、ACR/EULAR Boolean)T2T均呈持续正相关且持续T2T效应更明显。
要点
- 单次T2T未显著提高3个月后DAS44缓解(OR 1.03,95%CI 0.92–1.16)。
- 持续T2T(≥2次连续访视)提高DAS44缓解可能性(OR 1.19,95%CI 1.03–1.39)。
- 对CDAI、SDAI、ACR/EULAR Boolean缓解,T2T及持续T2T均呈正相关。
核心结论
- 日常实践中正确应用T2T策略(尤其持续T2T)可使RA患者获得更高缓解率。
研究设计与样本
- RA BIODAM队列纵向分析,纳入10国571例开始或更换csDMARDs或bDMARDs的RA患者,每3个月评估疾病活动度持续2年。
- 每次访视判定是否按T2T策略治疗,以DAS44缓解(DAS44<1.6)为目标;持续T2T定义为≥2次连续访视遵循T2T。
主要发现
- 共纳入4356次访视,患者平均(SD)年龄56(13)岁,女性占78%,适当应用T2T见于59%的访视。
- T2T(对比无T2T)未提高3个月后DAS44缓解可能性(OR 1.03,95%CI 0.92–1.16),但持续T2T提高DAS44缓解可能性(OR 1.19,95%CI 1.03–1.39)。
- DAS28-ESR缓解结果类似;对CDAI、SDAI和ACR/EULAR Boolean缓解,T2T均呈正相关(OR范围1.16–1.29),持续T2T效应更明显(OR范围1.49–1.52)。
关键数值与推荐
- T2T目标为DAS44缓解(DAS44<1.6),持续T2T定义为≥2次连续访视遵循T2T。
- 主要结局为后续3个月访视时达到DAS44缓解;其他结局包括DAS28-ESR、CDAI、SDAI和ACR/EULAR Boolean缓解。
临床怎么用
- 在RA日常管理中应坚持并持续执行T2T策略,而非仅单次访视达标,以提升缓解率。
- 对更严格缓解目标(CDAI、SDAI、ACR/EULAR Boolean),持续T2T的获益更为明显。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate whether following a treat-to-target (T2T)-strategy in daily clinical practice leads to more patients with rheumatoid arthritis (RA) meeting the remission target. METHODS: RA patients from 10 countries starting/changing conventional synthetic or biological disease-modifying anti-rheumatic drugs were assessed for disease activity every 3 months for 2 years (RA BIODAM (BIOmarkers of joint DAMage) cohort). Per visit was decided whether a patient was treated according to a T2T-strategy with 44-joint disease activity score (DAS44) remission (DAS44 <1.6) as the target. Sustained T2T was defined as T2T followed in ≥2 consecutive visits. The main outcome was the achievement of DAS44 remission at the subsequent 3-month visit. Other outcomes were remission according to 28-joint disease activity score-erythrocyte sedimentation rate (DAS28-ESR), Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean definitions. The association between T2T and remission was tested in generalised estimating equations models. RESULTS: In total 4356 visits of 571 patients (mean (SD) age: 56 (13) years, 78% female) were included. Appropriate application of T2T was found in 59% of the visits. T2T (vs no T2T) did not yield a higher likelihood of DAS44 remission 3 months later (OR (95% CI): 1.03 (0.92 to 1.16)), but sustained T2T resulted in an increased likelihood of achieving DAS44 remission (OR: 1.19 (1.03 to 1.39)). Similar results were seen with DAS28-ESR remission. For more stringent definitions (CDAI, SDAI and ACR/EULAR Boolean remission), T2T was consistently positively associated with remission (OR range: 1.16 to 1.29), and sustained T2T had a more pronounced effect on remission (OR range: 1.49 to 1.52). CONCLUSION: In daily clinical practice, the correct application of a T2T-strategy (especially sustained T2T) in patients with RA leads to higher rates of remission.
引用
- Ramiro S, Landewé RB, van der Heijde D, et al. Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). Ann Rheum Dis. 2020. PMID: 32094157. doi:10.1136/annrheumdis-2019-216819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。